|
|
|
| Effects of Tetramethylpyrazine Hydrochloride on Visual Acuity and Vascular Endothelial Function in NPDR Patients |
| WANG Qian, et al |
| PLA Army 82 Group Military Hospital, Hebei Baoding 071000, China |
|
|
|
|
Abstract Objective: To explore the effects of tetramethylpyrazine hydrochloride on visual acuity and vascular endothelial function in patients with non-prolifertive diabetic retinopathy (NPDR). Methods: A total of 142 patients with NPDR admitted to our hospital from October 2016 to October 2018 were selected and divided into two groups according to the simple random grouping. The two groups were given basic treatment, and 71 patients in control group were treated with calcium dobesilate tablets, and 71 patients in observation group were given tetramethylpyrazine hydrochloride tablets on the basis of control group. The treatment efficacy, and visual acuity, intraocular pressure, macular edema and macular thickness, and plasma vascular endothelial growth factor (VEGF), endothelin-1 (ET-1) and endothelium-dependent flow-mediated dilatation (FMD) before and after treatment were compared between the two groups. Results: The total effective rate of treatment in observation group was significantly higher than that in control group (92.96% vs 81.69%) (P<0.05). After treatment, the visual acuity in observation group was significantly better than that in control group (P<0.05), and the macular edema score was significantly lower than that in control group, and the macular thickness was significantly lower than that in control group (P<0.05). The levels of VEGF and ET-1 in observation group were significantly lower than those in control group while the FMD value was significantly higher than that in control group (P<0.05). However, there was no significant change in intraocular pressure between the two groups before and after treatment (P>0.05). Conclusion: Teramethylpyrazine hydrochloride can effectively improve the vision of NPDR patients, reduce macular edema and improve vascular endothelial function.
|
|
|
|
|
|
[1] 朱成义,伊琼,马金力,等.银杏叶提取物对糖尿病视网膜病变的临床疗效评价[J].国际眼科杂志,2016,16(2):361~364.
[2] 雯静,连凤梅,金德.药物干预非增殖期糖尿病视网膜病变临床研究进展[J].医学综述,2017,23(18):3665~3669.
[3] 汪怿,徐洁慧,李韧.川芎嗪治疗非增殖期糖尿病视网膜病变的临床疗效及其对血清HIF-1、VEGF的影响[J].中国临床药理学杂志,2015,31(14):1393~1395.
[4] 段俊国,金明,接传红.糖尿病视网膜病变中医防治指南[J].中国中医药现代远程教育,2011,9(4):154~155.
[5] 董文,颉瑞萍,刘勤.中医药治疗糖尿病视网膜病变研究进展[J].中国中医眼科杂志,2017,27(2):131~133.
[6] 杨瑾.行气化瘀中药治疗非增生性糖尿病视网膜病变疗效及对VEGF、Ang及ANGPT的影响[J].现代中西医结合杂志,2017,26(35):3923~3926.
[7] 任红苗,高志娟.川芎嗪注射液联合羟苯磺酸钙对糖尿病视网膜病变患者血流变学及脂联素水平的影响[J].辽宁中医药大学学报,2018,20(6):149~151.
[8] 王梦斐,王瑞夫,刘毅,等.四种血管内皮功能指标在糖尿病视网膜病变中的应用[J].国际眼科杂志,2017,17(1):110~112.
[9] 卢伟波,李舒敏,吕以培,等.前列地尔对早期糖尿病视网膜病变患者血管内皮功能的影响[J].山东医药,2013,53(24):50~52. |
|
|
|
2019, Vol. 25 
